Faculty, Staff and Student Publications
Language
English
Publication Date
1-1-2023
Journal
Frontiers in Nephrology
DOI
10.3389/fneph.2023.1168614
PMID
37675380
PMCID
PMC10479603
PubMedCentral® Posted Date
July 2023
PubMedCentral® Full Text Version
Post-print
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs have a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions. Acute kidney injury from ICIs has been well studied; incidence ranges from 1% to 5%, with higher incidence when combination ICI therapies are used. Although the overall reported incidence of ICI-associated glomerulonephritis is less than 1%, vasculitis is the most commonly reported ICI-related glomerulonephritis. Other biopsy findings include thrombotic microangiopathy, focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy with secondary amyloidosis. We report a case in which a woman previously treated with the PD-L1 inhibitor durvalumab for locally advanced non-small cell lung cancer with pre-existing antineutrophil cytoplasmic (anti-PR3) antibody who later developed multi-organ vasculitis after ICI exposure, which was successfully treated with rituximab, with continued cancer remission for 3 years.
Keywords
immune check inhibitor, autoimmune induction, vasculitis, acute renal failure, rituximab
Published Open-Access
yes
Recommended Citation
Qureshi, Sehrish; Arani, Naszrin; Parvathareddy, Vishnu; et al., "Case Report: Immune Checkpoint Inhibitor-Induced Multiorgan Vasculitis Successfully Treated With Rituximab" (2023). Faculty, Staff and Student Publications. 1983.
https://digitalcommons.library.tmc.edu/uthmed_docs/1983